VEXAS Syndrome and Alzheimer’s Disease—Are There Connections?
Open Access
- 26 May 2025
- journal article
- review article
- Published by MDPI AG in Brain Sciences
- Vol. 15 (6) , 573
Abstract
VEXAS syndrome and Alzheimer’s disease (AD), though distinct in clinical manifestations, share overlapping pathophysiological mechanisms, including systemic inflammation, protein misfolding, and vascular dysfunction. VEXAS syndrome, a rare autoinflammatory disorder characterized by somatic UBA1 mutations, systemic inflammation, and hematologic abnormalities, presents primarily in older males. Meanwhile, AD, the leading cause of dementia, involves progressive neurodegeneration driven by amyloid-beta plaques, tau tangles, and chronic neuroinflammation. This article explores potential connections between the two conditions, focusing on inflammation, neurovascular changes and cellular stress. Systemic inflammation observed in VEXAS syndrome may potentiate neuroinflammatory processes in Alzheimer’s disease (AD), as circulating proinflammatory cytokines have the capacity to cross the blood–brain barrier (BBB), thereby inducing glial activation and promoting neuroinflammation. Additionally, coexisting vascular dysfunctions characteristic of both conditions may synergistically contribute to accelerated cognitive decline. Both conditions involve disruption of the ubiquitin–proteasome system, with UBA1 mutations being specific to VEXAS. Given the established role of UBA1 in maintaining neuronal homeostasis, investigating the overlapping and distinct molecular mechanisms may provide valuable insights into their pathophysiology. The review underscores the need for further research to elucidate these links and improve therapeutic strategies, especially for individuals affected by both disorders.Keywords
This publication has 44 references indexed in Scilit:
- Single‐microglia transcriptomic transition network‐based prediction and real‐world patient data validation identifies ketorolac as a repurposable drug for Alzheimer's diseaseAlzheimer's & Dementia, 2024
- Central nervous system vasculitis in VEXAS syndrome: A rare involvemenClinical Neurology and Neurosurgery, 2024
- Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical PopulationJAMA, 2023
- Concerted type I interferon signaling in microglia and neural cells promotes memory impairment associated with amyloid β plaquesImmunity, 2022
- Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXASArthritis & Rheumatology, 2021
- 2020 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2020
- NIA‐AA Research Framework: Toward a biological definition of Alzheimer's diseaseAlzheimer's & Dementia, 2018
- Respiratory infection promotes T cell infiltration and amyloid-β deposition in APP/PS1 miceNeurobiology of Aging, 2014
- The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's diseaseAlzheimer's & Dementia, 2011
- Cholinesterase inhibitors for Alzheimer's diseaseCochrane Database of Systematic Reviews, 2006